Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317797 | 0.85 | PTGDR2 (0.80) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL316993 | 0.82 | PTGDR2 (0.76) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL317229 | 0.81 | PTGDR2 (1.00) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL316984 | 0.76 | PTGDR2 (0.67) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL317456 | 0.76 | PTGDR2 (1.00) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL317218 | 0.76 | PTGDR2 (0.76) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL317251 | 0.76 | PTGDR2 (0.66) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL318378 | 0.75 | PTGDR2 (0.66) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL27542506 | 0.75 | PTGDR2 (0.65) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 | |
| SCHEMBL317185 | 0.75 | PTGDR2 (0.66) | PTGDR2PTGS1CYP2C9SLC6A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | PTGDR2 59/4885PTGS1 107/4885CYP2C9 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.